Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)
Phase of Trial: Phase III
Latest Information Update: 03 Feb 2017
At a glance
- Drugs Dasatinib (Primary) ; Cytarabine; Daunorubicin
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 30 Jan 2017 Planned End Date changed from 1 Jul 2022 to 1 May 2023.
- 06 Dec 2016 Results assessing minimal residual disease monitoring in Acute Myeloid Leukemia study group (AML HD93, NCT00146120, NCT00151255, NCT00151242, NCT00850382 and NCT02013648 trials) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 18 Jul 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.